Overview
- Structure Therapeutics reported positive topline data for aleniglipron, a once-daily oral nonpeptide GLP-1 receptor agonist.
- In one study, the drug reached a placebo-adjusted mean weight loss of up to 15.3%, or 35.5 pounds.
- The company described a compelling off-target safety profile and said the findings support advancing into Phase 3.
- Shares surged intraday to a 52-week high of $94.90 and were up about 96.6%, trading at $67.93 at the time of publication, according to Benzinga Pro.
- Analysts estimate the obesity-drug market was roughly $15 billion in 2024 and could grow toward $150 billion by 2035, underscoring the commercial stakes while full datasets and Phase 3 results are still pending.